Celltrion to invest $47 mn in cancer-treating ADC developer Iksuda
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The Korean biotech major already has executed half of the investment. The remaining investment will be made immediately after pre-agreed development milestones are reached, according to Celltrion on Monday.
Celltrion will become the largest shareholder of Iksuda Therapeutics after the final investment. Mirae Asset Group’s asset management units are also taking part of the deal as investors.
Iksuda Therapeutics specializes in developing ADCs, a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Its ADC pipeline includes those for B-cell lymphomas, lung cancer and gynecological tumors.
Celltrion plans to leverage Iksuda Therapeutics’s ADC technology on further expanding its cancer treatment offerings beyond blood cancer drug Truxima and breast cancer drug Herzuma.
On Monday, Celltrion shares closed 0.56 percent lower at 265,500 won ($238.57).
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Temporary container ship trip to increase to 4 per month to meet surging US demand - Pulse by Maeil Business News Korea
- Korea’s Centroid Investment to name strategic partners next week - Pulse by Maeil Business News Korea
- K-bio names under limelight at ASCO for their headway in cancer diagnosis and treatment - Pulse by Maeil Business News Korea
- Some Korean corporate giants could be affected by G7 tax deal - Pulse by Maeil Business News Korea
- Celltrion to invest $47 mn in cancer-treating ADC developer Iksuda - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 리뷰하다 창업 50억 매출…문래동 다 잡았다 [대한민국 장사 고수 열전]
- 카니예 웨스트, 14년만 한국 온다…8월 23일 공연 확정[공식] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이